A Potential Turning Point for the Country’s 10-Crore Diabetes Burden
Novo Nordisk has rolled out Awiqli (insulin icodec) in India, marking the commercial debut of the world’s first once-weekly basal insulin for adults living with Type 1 and Type 2 diabetes. The launch is being positioned by the Danish pharmaceutical major as a structural change in insulin therapy — one that could cut the number of annual injections a patient needs from 365 to just 52, and, if adoption follows, reshape how a nation of over 10 crore diabetics engages with a mainstay of chronic disease management.
What Awiqli Is — and What Makes It Different
Awiqli is the brand name for insulin icodec, a long-acting basal insulin analogue engineered to bind reversibly to albumin in the bloodstream, allowing it to be released gradually over seven days rather than the roughly 24-hour action window of conventional basal insulins such as glargine or degludec. This pharmacokinetic design is what permits a single subcutaneous injection to replace a full week of daily dosing.
The product is delivered via a U-700 FlexTouch-style prefilled pen, a significantly higher concentration than standard insulin pens, engineered specifically to accommodate a week’s worth of basal insulin in one shot. In India, Novo Nordisk has priced a 700-unit pack at Rs 2,611, a figure the company says works out to roughly 30-40% cheaper than the cumulative cost of daily basal insulin units over an equivalent period — though on a per-unit basis, industry estimates place icodec pricing in the region of Rs 3.5 per unit, broadly in line with existing basal insulin analogues rather than at a discount to them. The net saving, therefore, appears to be driven less by a lower per-unit price and more by reduced wastage, fewer consumables (needles, syringes), and the compounding effect of fewer dispensing cycles — a distinction worth flagging for readers comparing sticker price to real-world cost of therapy.
Notably, India is among the relatively few markets where Awiqli has been approved for both Type 1 and Type 2 diabetes. In the United States, by contrast, the FDA has cleared insulin icodec only for Type 2 diabetes, citing residual safety concerns — particularly around hypoglycemia risk — in Type 1 patients, whose insulin requirements are typically more variable and dependent on precise titration. This makes India’s regulatory clearance comparatively broader in scope, and it is a point clinicians here will need to navigate carefully in practice.
The Injection-Burden Argument
The central pitch behind Awiqli is behavioural rather than purely biochemical: insulin therapy in India is frequently delayed, under-dosed, or abandoned altogether because of “injection anxiety” — a well-documented phenomenon in which patients, particularly at the point of insulin initiation, resist or postpone starting therapy out of fear of needles, social stigma, or the sheer daily burden of remembering and administering a shot. Novo Nordisk India’s leadership has framed the weekly dosing schedule as a direct answer to this resistance, arguing that cutting injection frequency by roughly 86% removes one of the largest psychological barriers to timely insulin initiation and sustained adherence.
This is not merely a comfort argument. Poor adherence to insulin regimens is a recognised driver of long-term glycemic deterioration and downstream complications — retinopathy, nephropathy, neuropathy, and cardiovascular disease — that impose enormous costs on India’s healthcare system. If a weekly formulation genuinely improves real-world adherence (as distinct from trial-controlled adherence), the clinical and economic case strengthens considerably.
What the Clinical Evidence Actually Shows
Awiqli’s approval rests on Novo Nordisk’s ONWARDS Phase 3a clinical programme, a set of six global trials involving thousands of participants with Type 1 and Type 2 diabetes, comparing insulin icodec against established daily basal insulins (glargine and degludec).
- Across the ONWARDS trials, icodec demonstrated non-inferiority — and in several trials, statistical superiority — in HbA1c reduction compared with daily basal insulin. A meta-analysis of the ONWARDS programme found an estimated treatment difference of roughly -0.14% in HbA1c versus daily comparators, alongside a higher likelihood of patients achieving HbA1c below 7% without significant hypoglycemia.
- Safety and hypoglycemia data are more nuanced than the “similar safety profile” framing suggests. In Type 2 diabetes participants, icodec was associated with a numerically lower or comparable rate of hypoglycemic events relative to daily insulin. In Type 1 diabetes participants, however, several ONWARDS trials — including data specific to Indian participants — recorded higher rates of hypoglycemia with icodec compared to daily basal insulin. This is a clinically important caveat, especially given India’s broader approval covering Type 1 patients, and it underscores why endocrinologists are likely to recommend more intensive glucose monitoring during the initiation phase.
- A dedicated analysis of 217 Indian participants drawn from the ONWARDS 1, 4, and 6 trials found HbA1c reductions with icodec that were statistically comparable to daily comparators, reinforcing that the drug’s efficacy profile translates reasonably well to the Indian patient population — though the sample size is modest relative to the scale of India’s diabetic population and should temper claims of population-wide certainty.
- Common adverse effects flagged across regulatory reviews (including by health technology bodies in Canada, which conducted an independent assessment) include hypoglycemia, injection site reactions, weight gain, hypersensitivity reactions, and fluid retention — a profile broadly consistent with the wider basal insulin class rather than materially worse.
Regulatory reviewers, including Canada’s health technology assessment body, have also noted that while the reduction in HbA1c reached statistical significance in some trials, the clinical significance of that incremental improvement remains a matter of ongoing scientific discussion. In plain terms: icodec appears to control blood sugar at least as well as — and modestly better than — daily insulin, but the “modestly better” component should not be overstated as a dramatic leap in glycemic control. The more defensible clinical case is convenience and adherence, not a categorical efficacy breakthrough.
Why This Matters for India’s Diabetes Burden
India’s diabetes numbers are, by any measure, staggering. The ICMR-INDIAB study, the most comprehensive national survey of its kind, estimates that over 10.1 crore (101 million) Indians are currently living with diabetes, with national adult prevalence at roughly 11.4%. Alongside this, an estimated 13.6 crore (136 million) Indians are living with prediabetes — a population at substantial future risk of conversion to overt diabetes without intervention. Prevalence varies sharply by geography, from over 26% in Goa to under 5% in Uttar Pradesh, reflecting uneven patterns of urbanisation, diet, and healthcare access.
Against this backdrop, insulin initiation in India has historically lagged behind clinical guidelines. Physicians frequently cite patient reluctance — rooted in the injection burden, fear of hypoglycemia, and the social stigma still attached to insulin use in many communities — as a major reason patients remain on oral therapy for longer than is clinically advisable, sometimes at the cost of years of suboptimal glycemic control. A once-weekly option, if it lives up to its adherence promise, targets precisely this gap in the treatment pathway rather than competing on efficacy with existing insulins.
The Caveats Journalists and Patients Should Weigh
A comprehensive, independent account of this launch cannot rest solely on the manufacturer’s framing. Several considerations merit scrutiny:
- Cost savings claims need context. The “30-40% cheaper” figure and the “20-25% lower annual cost” figures reported elsewhere are Novo Nordisk’s own comparative framing and are not fully reconcilable on a simple per-unit basis, since icodec’s per-unit price is reportedly comparable to, not below, existing basal insulins. The savings case rests on reduced consumable use and dosing efficiency — a legitimate but different argument than “the drug itself is cheaper.”
- Type 1 diabetes hypoglycemia risk is a real and reported finding, not a hypothetical concern, and Indian regulators’ decision to approve the drug for Type 1 use — broader than the US FDA’s more conservative Type 2-only approval — will likely draw continued clinical monitoring and possibly post-marketing surveillance.
- Titration and switching protocols matter. Regulatory reviews in other markets (including Canada’s Health Canada) flag elevated hypoglycemia risk specifically in the early days after dose initiation or when switching from another insulin, meaning patient education and physician oversight during the transition period will be critical to safe uptake.
- Long-term, real-world adherence data from India does not yet exist. The ONWARDS trials establish clinical non-inferiority in controlled settings; whether the drug meaningfully changes real-world insulin initiation and adherence rates in India — the central promise of the launch — is an empirical question that will only be answered once post-launch usage data accumulates.
The Bottom Line
Awiqli’s India launch is a genuine pharmacological milestone — the first time patients here can consider a basal insulin regimen requiring roughly one injection a week instead of seven. The clinical trial base, including India-specific ONWARDS data, supports its efficacy as broadly comparable to existing daily insulins, with the adherence and convenience argument being the drug’s strongest selling point rather than a dramatic gain in blood sugar control. For India’s Type 2 diabetes population in particular, this could meaningfully lower the psychological barrier to insulin initiation. For its Type 1 population, the higher recorded hypoglycemia rates in some trials warrant more cautious, closely monitored adoption. As with any major therapeutic launch, the real test will be measured not in clinical trial data but in how the drug performs across India’s vast, heterogeneous, and often under-monitored patient population over the coming years.
Kuppuswamy S
